{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Guanfacine",
    "query": {
      "condition": "Guanfacine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 56,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Guanfacine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T09:03:00.848Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04085172",
      "title": "A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Guanfacine hydrochloride (TAK-503)",
          "type": "DRUG"
        },
        {
          "name": "Atomoxetine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 396,
      "start_date": "2019-09-18",
      "completion_date": "2025-09-02",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-07-24T09:03:00.848Z",
      "location_count": 20,
      "location_summary": "Dothan, Alabama • Anaheim, California • Imperial, California + 17 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04085172"
    },
    {
      "nct_id": "NCT02048241",
      "title": "Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intermittent Explosive Disorder",
        "Childhood Aggression",
        "Oppositional Defiant Disorder",
        "Attention Deficit Disorder"
      ],
      "interventions": [
        {
          "name": "Parent Management Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Intuniv",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 11,
      "start_date": "2011-07",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2018-06-13",
      "last_synced_at": "2026-07-24T09:03:00.848Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02048241"
    },
    {
      "nct_id": "NCT05657860",
      "title": "Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Prader-Willi Syndrome",
        "Aggression",
        "Self-Injurious Behavior",
        "Pathologic Processes",
        "Behavioral Symptoms",
        "Intellectual Disability",
        "Neurobehavioral Manifestations",
        "Neurologic Manifestations",
        "Nervous System Diseases",
        "Abnormalities, Multiple",
        "Congenital Abnormalities",
        "Chromosome Disorders",
        "Genetic Diseases, Inborn",
        "Obesity",
        "Overnutrition",
        "Nutrition Disorders",
        "Antihypertensive Agents",
        "Neurotransmitter Agents",
        "Molecular Mechanisms of Pharmacological Action",
        "Physiological Effects of Drugs",
        "Skin-Picking"
      ],
      "interventions": [
        {
          "name": "Guanfacine Extended Release",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Maimonides Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "6 Years to 35 Years"
      },
      "enrollment_count": 15,
      "start_date": "2020-12-17",
      "completion_date": "2023-12-16",
      "has_results": false,
      "last_update_posted_date": "2024-08-19",
      "last_synced_at": "2026-07-24T09:03:00.848Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05657860"
    },
    {
      "nct_id": "NCT01146002",
      "title": "Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Guanfacine (sustained release)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurology Group of Bergen County, P.A.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-06",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2014-04-02",
      "last_synced_at": "2026-07-24T09:03:00.848Z",
      "location_count": 1,
      "location_summary": "Ridgewood, New Jersey",
      "locations": [
        {
          "city": "Ridgewood",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01146002"
    },
    {
      "nct_id": "NCT01156051",
      "title": "Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder",
        "Attention Deficit Disorder",
        "Insomnia",
        "Sleep Disorders"
      ],
      "interventions": [
        {
          "name": "Guanfacine extended-release tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Specialized Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 29,
      "start_date": "2010-06",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2014-08-11",
      "last_synced_at": "2026-07-24T09:03:00.848Z",
      "location_count": 2,
      "location_summary": "Hamilton, New Jersey • Toms River, New Jersey",
      "locations": [
        {
          "city": "Hamilton",
          "state": "New Jersey"
        },
        {
          "city": "Toms River",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01156051"
    },
    {
      "nct_id": "NCT00389779",
      "title": "DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Darusentan",
          "type": "DRUG"
        },
        {
          "name": "Guanfacine",
          "type": "DRUG"
        },
        {
          "name": "Darusentan Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 849,
      "start_date": "2006-09",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2014-03-18",
      "last_synced_at": "2026-07-24T09:03:00.848Z",
      "location_count": 87,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00389779"
    },
    {
      "nct_id": "NCT00358969",
      "title": "Guanfacine to Treat Borderline Personality Disorder",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Borderline Personality Disorder"
      ],
      "interventions": [
        {
          "name": "guanfacine (Tenex)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": null,
      "start_date": "2006-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-08-01",
      "last_synced_at": "2026-07-24T09:03:00.848Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00358969"
    },
    {
      "nct_id": "NCT01467999",
      "title": "Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cannabis Dependence"
      ],
      "interventions": [
        {
          "name": "Guanfacine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 22,
      "start_date": "2012-02",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2019-02-05",
      "last_synced_at": "2026-07-24T09:03:00.848Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01467999"
    },
    {
      "nct_id": "NCT03137082",
      "title": "Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Abstinence"
      ],
      "interventions": [
        {
          "name": "Guanfacine XR 3mgs/daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for guanfacine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2017-07-12",
      "completion_date": "2021-03-31",
      "has_results": true,
      "last_update_posted_date": "2024-06-05",
      "last_synced_at": "2026-07-24T09:03:00.848Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03137082"
    },
    {
      "nct_id": "NCT00585754",
      "title": "Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and Relapse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Dependent",
        "Alcohol Dependent"
      ],
      "interventions": [
        {
          "name": "Guanfacine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 75,
      "start_date": "2006-04",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-11-30",
      "last_synced_at": "2026-07-24T09:03:00.848Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00585754"
    }
  ]
}